CompletedNCT00374920
MEM 1003 for manic or mixed episodes in bipolarity type I
About this title
Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder
Read the official source — NCT00374920This study evaluated the safety and effectiveness of MEM 1003 for people with bipolarity.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of MEM 1003 for people with bipolarity.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 20 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateSeptember 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 60
- Sponsor
- Memory Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00374920
- Official title
Show the full official title
A Multicenter, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEM 1003 for the Treatment of Patients With Bipolar I Disorder Suffering Acute Manic or Mixed Episodes
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock · Garden Grove · Riverside
15 more locations
- San Diego
- Torrance
- Bradenton
- Fort Lauderdale
- Lake Charles
- Shreveport
- Boston
- Willingboro
- Philadelphia
- Austin
- Bellaire
- Dallas
- Houston
- Irving
- Kirkland
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of MEM 1003 for people with bipolarity.
Who is behind this study?
The study sponsor is Memory Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including MEM 1003.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
